会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS
    • 用于抑制光学缺陷的药物递送植入物
    • US20100114309A1
    • 2010-05-06
    • US12521543
    • 2007-12-21
    • Eugene de Juan, JR.Cary J. ReichStephen BoydHanson S. GiffordMark Deem
    • Eugene de Juan, JR.Cary J. ReichStephen BoydHanson S. GiffordMark Deem
    • A61F2/16
    • A61F9/0017A61F9/00772A61F9/00781A61K9/0051
    • An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.
    • 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中,以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中,眼睛的屈光性可以包括近视,远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如,治疗剂可以包括睫状肌麻痹症,其包括阿托品,环戊二酸酯,琥珀酰胆碱,同质素,东莨菪碱或托品酰胺中的至少一种。 在许多实施例中,保持元件可以附接到结构以沿着天然组织表面保持结构。